PCM
ALXN

Pentwater Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Pentwater Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,000
Closed -$2.45M – 125
2016
Q4 		$2.45M Buy
+20,000
New +$2.45M 0.03% 95

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Pentwater Capital Management's ALXN Position: Q3 2021 in Review

Pentwater Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,933,200 shares — an estimated $906M sold.

Pentwater Capital Management first reported a position in ALXN in Q4 2016 and held it in 5 quarters. The position peaked at $906M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Pentwater Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 4,933,200 Alexion Pharmaceuticals shares in Q3 2021, an estimated $906M.
  • Pentwater Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Pentwater Capital Management's Alexion Pharmaceuticals position peaked at $906M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.